Improvement in health-related quality of life in children with ADHD

An analysis of placebo controlled studies of atomoxetine

Amy R. Perwien, Douglas E. Faries, Christopher J Kratochvil, Calvin R. Sumner, Douglas K. Kelsey, Albert J. Allen

Research output: Contribution to journalArticle

81 Citations (Scopus)

Abstract

Despite significant functional impairments associated with attention-deficit hyperactivity disorder (ADHD) and the growing appreciation of the importance of health-related quality of life (HRQL) assessment in children with chronic disorders, relatively few studies have examined the impact of ADHD treatment on HRQL. This investigation examines the effect of atomoxetine, a nonstimulant treatment for ADHD, on HRQL and identifies factors that are predictive of HRQL improvements. The Child Health Questionnaire (CHQ), which is a multidimensional HRQL measure, was collected during three randomized, double-blind, placebo-controlled clinical trials. Children who received atomoxetine had significantly greater improvement in psychosocial functioning compared to the placebo group. No significant differences between once-a-day and twice-a-day dosing were found. Treatment with atomoxetine, lower HRQL baseline score, no history of stimulant use, and absence of oppositional defiant disorder were all associated with improvements in psychosocial functioning. Findings demonstrate the positive impact of atomoxetine on HRQL in children with ADHD.

Original languageEnglish (US)
Pages (from-to)264-271
Number of pages8
JournalJournal of Developmental and Behavioral Pediatrics
Volume25
Issue number4
DOIs
StatePublished - Aug 1 2004

Fingerprint

Attention Deficit Disorder with Hyperactivity
Placebos
Quality of Life
Attention Deficit and Disruptive Behavior Disorders
Controlled Clinical Trials
Quality Improvement
Atomoxetine Hydrochloride
Therapeutics

Keywords

  • Attention-deficit hyperactivity disorder (ADHD)
  • Clinical trials
  • Health-related quality of life (HRQL)
  • Pharmacological treatment

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Developmental and Educational Psychology
  • Psychiatry and Mental health

Cite this

Improvement in health-related quality of life in children with ADHD : An analysis of placebo controlled studies of atomoxetine. / Perwien, Amy R.; Faries, Douglas E.; Kratochvil, Christopher J; Sumner, Calvin R.; Kelsey, Douglas K.; Allen, Albert J.

In: Journal of Developmental and Behavioral Pediatrics, Vol. 25, No. 4, 01.08.2004, p. 264-271.

Research output: Contribution to journalArticle

Perwien, Amy R. ; Faries, Douglas E. ; Kratochvil, Christopher J ; Sumner, Calvin R. ; Kelsey, Douglas K. ; Allen, Albert J. / Improvement in health-related quality of life in children with ADHD : An analysis of placebo controlled studies of atomoxetine. In: Journal of Developmental and Behavioral Pediatrics. 2004 ; Vol. 25, No. 4. pp. 264-271.
@article{36557c7b8ed04f1fafb384e600497a5f,
title = "Improvement in health-related quality of life in children with ADHD: An analysis of placebo controlled studies of atomoxetine",
abstract = "Despite significant functional impairments associated with attention-deficit hyperactivity disorder (ADHD) and the growing appreciation of the importance of health-related quality of life (HRQL) assessment in children with chronic disorders, relatively few studies have examined the impact of ADHD treatment on HRQL. This investigation examines the effect of atomoxetine, a nonstimulant treatment for ADHD, on HRQL and identifies factors that are predictive of HRQL improvements. The Child Health Questionnaire (CHQ), which is a multidimensional HRQL measure, was collected during three randomized, double-blind, placebo-controlled clinical trials. Children who received atomoxetine had significantly greater improvement in psychosocial functioning compared to the placebo group. No significant differences between once-a-day and twice-a-day dosing were found. Treatment with atomoxetine, lower HRQL baseline score, no history of stimulant use, and absence of oppositional defiant disorder were all associated with improvements in psychosocial functioning. Findings demonstrate the positive impact of atomoxetine on HRQL in children with ADHD.",
keywords = "Attention-deficit hyperactivity disorder (ADHD), Clinical trials, Health-related quality of life (HRQL), Pharmacological treatment",
author = "Perwien, {Amy R.} and Faries, {Douglas E.} and Kratochvil, {Christopher J} and Sumner, {Calvin R.} and Kelsey, {Douglas K.} and Allen, {Albert J.}",
year = "2004",
month = "8",
day = "1",
doi = "10.1097/00004703-200408000-00006",
language = "English (US)",
volume = "25",
pages = "264--271",
journal = "Journal of Developmental and Behavioral Pediatrics",
issn = "0196-206X",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Improvement in health-related quality of life in children with ADHD

T2 - An analysis of placebo controlled studies of atomoxetine

AU - Perwien, Amy R.

AU - Faries, Douglas E.

AU - Kratochvil, Christopher J

AU - Sumner, Calvin R.

AU - Kelsey, Douglas K.

AU - Allen, Albert J.

PY - 2004/8/1

Y1 - 2004/8/1

N2 - Despite significant functional impairments associated with attention-deficit hyperactivity disorder (ADHD) and the growing appreciation of the importance of health-related quality of life (HRQL) assessment in children with chronic disorders, relatively few studies have examined the impact of ADHD treatment on HRQL. This investigation examines the effect of atomoxetine, a nonstimulant treatment for ADHD, on HRQL and identifies factors that are predictive of HRQL improvements. The Child Health Questionnaire (CHQ), which is a multidimensional HRQL measure, was collected during three randomized, double-blind, placebo-controlled clinical trials. Children who received atomoxetine had significantly greater improvement in psychosocial functioning compared to the placebo group. No significant differences between once-a-day and twice-a-day dosing were found. Treatment with atomoxetine, lower HRQL baseline score, no history of stimulant use, and absence of oppositional defiant disorder were all associated with improvements in psychosocial functioning. Findings demonstrate the positive impact of atomoxetine on HRQL in children with ADHD.

AB - Despite significant functional impairments associated with attention-deficit hyperactivity disorder (ADHD) and the growing appreciation of the importance of health-related quality of life (HRQL) assessment in children with chronic disorders, relatively few studies have examined the impact of ADHD treatment on HRQL. This investigation examines the effect of atomoxetine, a nonstimulant treatment for ADHD, on HRQL and identifies factors that are predictive of HRQL improvements. The Child Health Questionnaire (CHQ), which is a multidimensional HRQL measure, was collected during three randomized, double-blind, placebo-controlled clinical trials. Children who received atomoxetine had significantly greater improvement in psychosocial functioning compared to the placebo group. No significant differences between once-a-day and twice-a-day dosing were found. Treatment with atomoxetine, lower HRQL baseline score, no history of stimulant use, and absence of oppositional defiant disorder were all associated with improvements in psychosocial functioning. Findings demonstrate the positive impact of atomoxetine on HRQL in children with ADHD.

KW - Attention-deficit hyperactivity disorder (ADHD)

KW - Clinical trials

KW - Health-related quality of life (HRQL)

KW - Pharmacological treatment

UR - http://www.scopus.com/inward/record.url?scp=4444362262&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4444362262&partnerID=8YFLogxK

U2 - 10.1097/00004703-200408000-00006

DO - 10.1097/00004703-200408000-00006

M3 - Article

VL - 25

SP - 264

EP - 271

JO - Journal of Developmental and Behavioral Pediatrics

JF - Journal of Developmental and Behavioral Pediatrics

SN - 0196-206X

IS - 4

ER -